Opinion|Videos|September 5, 2024
Navigating Treatment Decisions in Chronic GVHD
Medical experts discuss criteria for switching GVHD treatments and how to choose between available treatment options.
Advertisement
Video content above is prompted by the following:
- What are the criteria for switching to another treatment?
How do you establish that the patient is not responding well to steroids/is steroid-refractory?
How long should one wait before switching to a second-line treatment?
- How do you choose between available treatment options after initial treatment in the second line?
Advertisement
Related to this article
No efficacy benefit was found in adding SBRT to dual checkpoint blockade, though a subset of patients responded to nivolumab plus ipilimumab.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, melanoma, ovarian cancer, prostate cancer, and hepatocellular carcinoma.
Data from EXCALIBER-RRMM supported FDA accelerated approval of iberdomide plus daratumumab/dexamethasone in R/R multiple myeloma.
The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.
Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.
Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR-TKI-pretreated advanced clear cell renal cell carcinoma.
A new study suggests genomic newborn screening could identify children at risk for early cancers and enable earlier diagnosis and less toxic treatment.
The CLDN18.2/CD47 bispecific antibody spevatamig has received FDA fast track designation for advanced and metastatic biliary tract carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
3
Five Under 5: Top Oncology Videos for the Week of 8/9
4
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
5